ANNX — Recent News Coverage

All news mentioning ANNX in ESEN's AI-graded feed

News stories with ANNX as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on ANNX. See /coverage/ANNX for the 30-day aggregate.

7 articles Updated: 2026-09-05 13:00 UTC Filter: Ticker: $ANNX
SEEKINGALPHA.COM · 2026-08-12 LOW NEUTRAL CORR0.15

Annexon outlines Q4 BLA filing for tanruprubart while adding month 24 dual primary endpoint to ARCHER II (NASDAQ:ANNX)

$ANNX
◈ ESEN AI
Annexon (ANNX) disclosed routine clinical trial milestones during its Q2 2026 earnings call, including plans to file a Biologics License Application (BLA) for tanruprubart in Q4 and expansion of the ARCHER II Phase III …
SEEKINGALPHA.COM · 2026-08-12 LOW NEUTRAL CORR0.15

Annexon, Inc. (ANNX) Q2 2026 Earnings Call Transcript

$ANNX
◈ ESEN AI
ANNX released its Q2 2026 earnings call transcript on August 12, 2026. As a procedural disclosure of scheduled earnings communication, this announcement carries routine informational value rather than catalytic market i…
MANILATIMES.NET · 2026-08-12 LOW BULLISH CORR0.42

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

$ANNX
◈ ESEN AI
Annexon Pharmaceuticals (ANNX) disclosed Q2 2026 financial results alongside clinical and operational updates for its lead candidate tanruprubart in Guillain-Barré Syndrome (GBS). The announcement details positive outco…
MANILATIMES.NET · 2026-07-16 LOW NEUTRAL CORR0.15

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

$ANNX
◈ ESEN AI
Annexon (ANNX) announced routine equity inducement grants to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved July 12, 2026. This disclosure reflects standard corporate governanc…
RTTNEWS.COM · 2026-07-16 NEUTRAL BULLISH CORR0.35

Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data

$APLM $IOVA $RCEL $ANNX $MANE
◈ ESEN AI
APLM's 22% gain reflects a technical relief rally following Nasdaq compliance restoration rather than fundamental clinical advancement. This type of listing-status recovery typically generates short-term momentum in mic…
SEEKINGALPHA.COM · 2026-07-14 NEUTRAL BULLISH CORR0.35

Annexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX)

$ANNX
◈ ESEN AI
ANNX is positioned as a speculative biotech play with near-term clinical catalysts, particularly centered on tanruprubart for Guillain-Barré syndrome treatment. The framing as a "high-risk/high-reward Buy" underscores t…
MANILATIMES.NET · 2026-06-16 LOW NEUTRAL CORR0.15

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

$ANNX
◈ ESEN AI
Annexon Inc. (ANNX) disclosed routine equity compensation grants to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved June 13, 2026. The announcement reflects standard hiring-rela…
EXPLORE OTHER FILTERS